Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, January 24, 2020
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
[ Fri, Jan 24th 2020
] - WOPRAI
Thu, January 23, 2020
[ Thu, Jan 23rd 2020
] - WOPRAI
[ Thu, Jan 23rd 2020
] - WOPRAI
[ Thu, Jan 23rd 2020
] - WOPRAI
[ Thu, Jan 23rd 2020
] - WOPRAI
[ Thu, Jan 23rd 2020
] - WOPRAI
[ Thu, Jan 23rd 2020
] - WOPRAI
[ Thu, Jan 23rd 2020
] - WOPRAI
[ Thu, Jan 23rd 2020
] - WOPRAI
[ Thu, Jan 23rd 2020
] - WOPRAI
[ Thu, Jan 23rd 2020
] - WOPRAI
Matthew Taylor Maintained (ABT) at Strong Buy with Increased Target to $105 on, Jan 23rd, 2020
Matthew Taylor of UBS, Maintained "Abbott Laboratories" (ABT) at Strong Buy with Increased Target from $99 to $105 on, Jan 23rd, 2020.
Matthew has made no other calls on ABT in the last 4 months.
There are 3 other peers that have a rating on ABT. Out of the 3 peers that are also analyzing ABT, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Christopher Pasquale of "Guggenheim" Downgraded from Strong Buy to Hold on, Thursday, January 2nd, 2020
These are the ratings of the 2 analyists that currently disagree with Matthew
- David Lewis of "Morgan Stanley" Maintained at Buy with Increased Target to $101 on, Tuesday, December 17th, 2019
- Matt Miksic of "Credit Suisse" Maintained at Buy with Increased Target to $98 on, Thursday, October 17th, 2019
